UCBJF:OTCMKTS
UCB SA
239,14Â US$
arrow_downward
−0,46%(−1,10) 1 d
16 okt., 16:00:00 GMT−4 · USD
search
Alla symboler
| Symbol | Pris | Ändring | Ändring i procent |
|---|
insights_autoGenererar de viktigaste insikterna för UCBJF …
Öppen
239,14Â US$
Högt
239,14Â US$
LÃ¥gt
239,14Â US$
Börsvärde
38,32Â md
Genomsn. vol.
127,00
Volym
107,00
52v högst
345,39Â US$
52v lägst
219,60Â US$
Beta
0,58
Utestående aktier
194,51Â mn
Antal anställda
9Â tn
Öppen
239,14Â US$
Högt
239,14Â US$
LÃ¥gt
239,14Â US$
Börsvärde
38,32Â md
Genomsn. vol.
127,00
Volym
107,00
52v högst
345,39Â US$
52v lägst
219,60Â US$
Beta
0,58
Utestående aktier
194,51Â mn
Antal anställda
9Â tn
Nyheter och artiklar
Från webbkällor och nyhetspartner
ad-hoc-news.de
·
för 17 timmar sedan
UCB revises Bimzelx potential above EUR 7 billion: UCB stock sits 30.28 percent below its high
ad-hoc-news.de
·
för 1 dag sedan
UCB dedicates Georgia campus as UCB stock sits 29.15 percent below its high
Profil
UCB is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease. The company's efforts are focused on treatments for severe diseases treated by specialists, particularly in the fields of central nervous system disorders, inflammatory disorders, and oncology.
Every three years, the company presents the UCB Award under the patronage of the Queen Elisabeth Medical Foundation to promote neuroscience research. The winner of this award is selected by an independent scientific committee. Wikipedia
Om UCB SA